Research Analysts Set Expectations for Halozyme Therapeutics, Inc.’s Q3 2025 Earnings (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Equities research analysts at Zacks Research increased their Q3 2025 EPS estimates for Halozyme Therapeutics in a research report issued on Monday, April 22nd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn $1.01 per share for the quarter, up from their prior estimate of $0.98. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.45 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2025 earnings at $3.92 EPS and Q1 2026 earnings at $1.21 EPS.

Several other brokerages have also weighed in on HALO. The Goldman Sachs Group cut their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. Morgan Stanley reduced their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 26th. TD Cowen started coverage on Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 target price on the stock. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 23rd. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, April 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $53.29.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO opened at $38.71 on Tuesday. The stock has a market capitalization of $4.92 billion, a P/E ratio of 18.35, a P/E/G ratio of 0.45 and a beta of 1.25. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89. Halozyme Therapeutics has a 1-year low of $29.85 and a 1-year high of $45.00. The business has a 50-day moving average price of $39.56 and a two-hundred day moving average price of $37.77.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the transaction, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at $6,473,094.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 30,000 shares of company stock valued at $1,196,800. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Rise Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth about $25,000. Principal Securities Inc. bought a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $34,000. First Horizon Advisors Inc. increased its position in shares of Halozyme Therapeutics by 24.5% during the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 293 shares during the last quarter. Parkside Financial Bank & Trust bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $64,000. Finally, Headlands Technologies LLC raised its stake in shares of Halozyme Therapeutics by 1,068.2% during the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 1,613 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.